We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-21.22%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.48B
AUM Growth
-$2.59B
Cap. Flow
-$1.26B
Cap. Flow %
-13.32%
Top 10 Hldgs %
78.76%
Holding
139
New
5
Increased
29
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$300M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$200M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$81.4M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$68.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$56.3M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$313M
2
GILD icon
Gilead Sciences
GILD
+$25.3M
3
MDVN
MEDIVATION, INC.
MDVN
+$12M
4
CPRX
Catalyst Pharmaceutical
CPRX
+$4.31M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$4.11M

Sector Composition

Rank Sector Weight
1 Healthcare 77.25%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
51
Ligand Pharmaceuticals
LGND
$5.76B
$7.86M 0.08%
117,638
– –
RARE icon
52
Ultragenyx Pharmaceutical
RARE
$2.49B
$7.84M 0.08%
123,894
– –
SAGE
53
DELISTED
Sage Therapeutics
SAGE
$7.18M 0.08%
224,048
+119,048
+113% +$4.19M
MGNX icon
54
MacroGenics
MGNX
$235M
$6.82M 0.07%
363,676
– –
CNCE
55
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$6.77M 0.07%
495,908
– –
PRQR icon
56
ProQR Therapeutics
PRQR
$243M
$6.59M 0.07%
1,349,719
+361,420
+37% +$1.84M
CPRX
57
DELISTED
Catalyst Pharmaceutical
CPRX
$6.43M 0.07%
5,498,459
-2,777,171
-34% -$4.31M
DERM
58
DELISTED
Dermira, Inc.
DERM
$5.69M 0.06%
275,000
– –
AKTX
59
Akari Therapeutics
AKTX
$14.8M
$5.54M 0.06%
495
– –
IOVA icon
60
Iovance Biotherapeutics
IOVA
$2.03B
$5.42M 0.06%
1,066,285
-751,144
-41% -$4.11M
ECYT
61
DELISTED
Endocyte, Inc. Common Stock
ECYT
$5.26M 0.06%
1,695,865
– –
ARWR icon
62
Arrowhead Research
ARWR
$11.9B
$4.87M 0.05%
1,009,509
– –
NDRM
63
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$4.31M 0.05%
305,000
– –
NTRA icon
64
Natera
NTRA
$35.8B
$4.28M 0.05%
450,000
+200,000
+80% +$1.69M
VTAE
65
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$4.23M 0.04%
637,597
+450,000
+240% +$4.09M
RXDX
66
DELISTED
Ignyta, Inc.
RXDX
$3.87M 0.04%
571,000
– –
LOXO
67
DELISTED
Loxo Oncology, Inc
LOXO
$3.77M 0.04%
137,735
– –
TRVN
68
DELISTED
Trevena, Inc.
TRVN
$3.72M 0.04%
720
– –
AERI
69
DELISTED
Aerie Pharmaceuticals
AERI
$3.64M 0.04%
299,356
– –
AIMT
70
DELISTED
Aimmune Therapeutics
AIMT
$3.39M 0.04%
250,000
– –
GNMX
71
DELISTED
Aevi Genomic Medicine Inc
GNMX
$3.37M 0.04%
765,000
– –
MCRB icon
72
Seres Therapeutics
MCRB
$46.1M
$3.32M 0.04%
6,250
– –
CRIS icon
73
Curis
CRIS
$9.67M
$3.22M 0.03%
1,000
– –
NBRV
74
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.14M 0.03%
1,400
– –
JUNO
75
DELISTED
Juno Therapeutics, Inc.
JUNO
$3.05M 0.03%
80,000
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2016 Portfolio in Review

As of Q1 2016, Baker Bros. Advisors held 139 positions worth $9.48B, down 21% from $12.1B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Baker Bros. Advisors withdrew a net $1.26B in Q1 2016, closing 5 positions and reducing 8 holdings. Its most notable exit was DYAX CORPORATION, an estimated $313M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 73% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in BeOne Medicines Ltd worth $56.1M.

  • Baker Bros. Advisors's largest Q1 2016 buy was BeOne Medicines Ltd: 1,912,680 shares worth $56.1M.
  • Baker Bros. Advisors added most to Incyte in Q1 2016, an estimated $300M increase.
  • Baker Bros. Advisors's biggest Q1 2016 reduction was MEDIVATION, INC., cutting an estimated $12M.
  • Baker Bros. Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $313M.
  • Baker Bros. Advisors's ten largest holdings make up 79% of its $9.48B portfolio in Q1 2016.
  • Baker Bros. Advisors opened 5 new positions and closed 5 in Q1 2016.
  • Baker Bros. Advisors's portfolio value fell 21% quarter-over-quarter to $9.48B.

Based on Baker Bros. Advisors's 13F filing for Q1 2016, filed 16 May 2016.